AUTHORS
Francesco Autore, MD, Annamaria Frustaci, MD2, Annarita Conconi3, Giulia Benevolo, MD4, Nicolò Danesin, MD5, Diana Giannarelli6, Ilaria Del Giudice7, Antonella Anastasia, MD8, Carola Boccomini9, Rita Rizzi10, Maura Nicolosi, MD11, Emanuele Cencini12, Raffaella Pasquale13, Claudia Bellofiore, MD14, Sara Steffanoni15, Martina Bullo16, Dario Marino, MD, PhD17, Massimo Gentile18, Giorgia D'Uva19, Idanna Innocenti, MD, PhD20, Luca Stirparo21, Jacopo Olivieri, MD22, Francesco Piazza, MD23, Simone Ferrero, MD24, Luca Arcaini25, Alessandra Tedeschi26, Luca Laurenti Sr, MD27, Stefano Luminari Sr, MD28
AFFILIATIONS
1 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
2 Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
3 Azienda sanitaria locale, Ematologia, Ospedale degli Infermi, Biella, Italy
4 Ematologia Universitaria A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
5 Hematology Unit, Department of Medicine, University of Padova, Padova, Italy, Pdova, Italy
6 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
7 Ematologia, Dipartimento di Medicina Traslazionale e di Precisione, Sapienza Università di Roma, Roma, Italy
8 ASST Spedali Civili, Brescia, Italy
9 SC Ematologia, AOU Città della Salute e della Scienza,, Torino, Italy
10 Università degli Studi 'Aldo Moro,' A.O.U. Consorziale Policlinico di Bari, Bari, Italy
11 SC Ematologia, AOU Città della Salute e della Scienza,, Torino, Italy
12 A.O.U. Senese e Università di Siena,, Siena, Italy
13 Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
14 Divisione di Ematologia e Trapianto di Midollo Osseo, Policlinico Gaspare Rodolico di Catania, Catania, Italy
15 Centro Valduce di Como, Como, Italy
16 Ordine Mauriziano di Torino, Torino, Italy
17 Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
18 Azienda Ospedaliera di Cosenza, Cosenza, Italy
19 Ematologia Universitaria A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
20 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
21 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
22 Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
23 Hematology Unit, Department of Medicine, University of Padova, Padova, Italy, Pdova, Italy
24 Ematologia Universitaria A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
25 Dipartimento di Medicina Molecolare, Università di Pavia, Pavia; Divisione di Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia;, Pavia, Italy
26 Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
27 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
28 Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia,, Reggio Emilia, Italy
ABSTRACT
The prolonged survival of patients with Waldenström Macroglobulinemia (WM) has raised concerns about long-term complications, including second primary malignancies (SPMs), and real-world data remain limited. We aimed to evaluate, in a multicenter real-life cohort, the incidence, type, and risk factors of SPMs in WM patients treated with bendamustine-rituximab (BR), and to compare them with follicular lymphoma (FL), treated with BR in the FIL FOLL12 trial. FL represents an ideal comparator, as both diseases are commonly treated with frontline BR but differ substantially in their underlying biology and natural history.
We retrospectively analyzed 168 WM patients (median follow-up 6.8 years) and 341 FL patients (median follow-up 8.4 years). Median age at diagnosis was 65 years (IQR 57–74) in WM and 64 (IQR 55–71) in FL; M/F ratio was 2.2 vs 0.7, respectively.
In WM, median overall survival (OS) was not reached, while median progression-free survival (PFS) was 8.9 years and event-free survival (EFS, time to relapse, death from any cause, or SPM) was 6.8 years. Fifty patients (29.8%) relapsed, and 44 (26.2%) received second-line therapy. Considering only the time between first line with BR until starting of second line or at last follow-up for patients who did not receive a second line treatment, SPMs occurred in 15 WM patients (9.1%; male 10.6%, 12 out of 113 vs female 5.8%, 3 out of 52): 12 solid (4 prostate and 2 colorectal carcinomas, 1 melanoma, 1 hepatocarcinoma, 1 esophagus carcinoma, 1 urothelial and 1 neuroendocrine neoplasm, 1 seminoma) and 3 hematologic (2 myelodysplastic syndromes, 1 acute myeloid leukemia).
In FL, OS, PFS, and EFS were not reached; 105 patients (30.8%) relapsed and 75 (22%) received second-line therapy. In the same condition, SPMs occurred in 27 patients (7.9%, male 8.6%, 12 out of 139 vs female 7.4%, 15 out of 202): 25 solid tumors (7 breast, 5 colorectal, 3 lung, 2 gastric, 1 bladder, 1 parotid, 1 thyroid, 1 melanoma, 1 myosarcoma, 1 neuroendocrine, and 2 unknown primary site) and 2 hematologic (2 myelodysplastic syndromes).
Cumulative SPM incidence in WM was 8.3% and 16.2% at 48- and 96-month, respectively, vs 5.9% and 9.7% in FL. The incidence observed in WM is consistent with previous reports (Leblond et al., Leukemia 2026 in which SPM cumulative incidence was 17.6% at 96 months, p=0.79). WM patients showed a higher incidence of SPMs at 96 months compared to FL (p=0.03). Deaths related to SPMs were proportionally more frequent in WM (8/31, 25.8%) than in FL (10/64, 15.6%).
In conclusion, WM patients treated with BR showed a higher incidence of SPMs than FL patients treated with the same regimen, suggesting that disease-specific factors, in addition to treatment exposure, may contribute to the increased oncologic risk. These findings support structured long-term surveillance and prevention of tumor risk factors in WM and prospective studies to clarify the drivers of increased oncologic risk, including treatment, disease biology, and patient susceptibility.
DISCLOSURES
Francesco Autore, MD: No relevant conflicts of interest to declare.